Compare Cadila Healthcare with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs LUPIN - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE LUPIN CADILA HEALTHCARE/
LUPIN
 
P/E (TTM) x 29.8 -301.4 - View Chart
P/BV x 4.8 3.9 122.1% View Chart
Dividend Yield % 0.7 0.6 130.5%  

Financials

 CADILA HEALTHCARE   LUPIN
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
LUPIN
Mar-20
CADILA HEALTHCARE/
LUPIN
5-Yr Chart
Click to enlarge
High Rs352882 39.9%   
Low Rs207505 40.9%   
Sales per share (Unadj.) Rs139.2339.4 41.0%  
Earnings per share (Unadj.) Rs11.8-5.9 -197.8%  
Cash flow per share (Unadj.) Rs18.615.5 120.0%  
Dividends per share (Unadj.) Rs3.506.00 58.3%  
Dividend yield (eoy) %1.30.9 144.8%  
Book value per share (Unadj.) Rs101.4276.7 36.6%  
Shares outstanding (eoy) m1,023.74453.00 226.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.02.0 98.2%   
Avg P/E ratio x23.7-116.6 -20.4%  
P/CF ratio (eoy) x15.044.8 33.6%  
Price / Book Value ratio x2.82.5 110.0%  
Dividend payout %29.8-100.9 -29.5%   
Avg Mkt Cap Rs m286,033314,201 91.0%   
No. of employees `00013.418.3 73.2%   
Total wages/salary Rs m24,14529,868 80.8%   
Avg. sales/employee Rs Th10,632.78,400.6 126.6%   
Avg. wages/employee Rs Th1,801.21,632.0 110.4%   
Avg. net profit/employee Rs Th898.5-147.2 -610.4%   
INCOME DATA
Net Sales Rs m142,531153,748 92.7%  
Other income Rs m1,1394,838 23.5%   
Total revenues Rs m143,670158,585 90.6%   
Gross profit Rs m24,19824,849 97.4%  
Depreciation Rs m6,9659,702 71.8%   
Interest Rs m3,4183,630 94.2%   
Profit before tax Rs m14,95416,355 91.4%   
Minority Interest Rs m2884 7,384.6%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m3,19811,571 27.6%   
Profit after tax Rs m12,044-2,694 -447.1%  
Gross profit margin %17.016.2 105.0%  
Effective tax rate %21.470.8 30.2%   
Net profit margin %8.5-1.8 -482.3%  
BALANCE SHEET DATA
Current assets Rs m87,154154,132 56.5%   
Current liabilities Rs m82,69492,252 89.6%   
Net working cap to sales %3.140.2 7.8%  
Current ratio x1.11.7 63.1%  
Inventory Days Days7182 87.0%  
Debtors Days Days94129 72.6%  
Net fixed assets Rs m133,23689,082 149.6%   
Share capital Rs m1,024906 113.0%   
"Free" reserves Rs m102,733124,461 82.5%   
Net worth Rs m103,757125,367 82.8%   
Long term debt Rs m32,14617,933 179.3%   
Total assets Rs m236,866249,839 94.8%  
Interest coverage x5.45.5 97.6%   
Debt to equity ratio x0.30.1 216.6%  
Sales to assets ratio x0.60.6 97.8%   
Return on assets %6.50.4 1,742.6%  
Return on equity %11.6-2.1 -540.2%  
Return on capital %13.78.7 157.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75251,450 102.5%   
Fx outflow Rs m14,50419,470 74.5%   
Net fx Rs m38,24831,980 119.6%   
CASH FLOW
From Operations Rs m25,05414,688 170.6%  
From Investments Rs m-10,12311,070 -91.4%  
From Financial Activity Rs m-10,942-8,906 122.9%  
Net Cashflow Rs m3,98916,853 23.7%  

Share Holding

Indian Promoters % 74.8 46.6 160.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.3 11.3 73.5%  
FIIs % 5.9 31.9 18.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.1 108.9%  
Shareholders   44,069 98,259 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   WOCKHARDT  J.B.CHEMICALS  SHASUN PHARMA  BIOCON   FULFORD INDIA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)

Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 20, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS